Back to resultsA Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
Primary Purpose
End Stage Renal Disease
Status
Terminated
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Hemoaccess Valve System
Sponsored by
About this trial
This is an interventional device feasibility trial for End Stage Renal Disease focused on measuring dialysis, vascular access, arteriovenous grafts, valve system
Eligibility Criteria
Inclusion Criteria:
- Be a candidate for a new arteriovenous graft
- Be either currently on dialysis or ready to begin dialysis as soon as the access device (AV graft with Hemoaccess Valve System) is ready for use.
- Be prepared to receive dialysis at dialysis centers in proximity of study centers
- Have an outflow vein of greater than or equal to 3mm in diameter to which the graft can be successfully anastomosed.
- Be able to communicate with study personnel.
- Be considered by the physician to be readily available for subsequent visits.
- Be willing to comply with all aspects of the treatment and evaluation as directed over the duration of the study.
- Allow representatives of the Sponsor, the designated Clinical Research Organization, the Institutional Review Board and the FDA to review his/her relevant medical records that pertain to this study.
Exclusion Criteria:
- An identification of a central venous stenosis on the ipsilateral side is documented or otherwise identified
- An identification of an arterial venous stenosis on the ipsilateral side is documented or otherwise identified
- A hypercoagulable state is documented or otherwise identified and/or previous AV access failures have occurred without an identifiable cause.
- Has a life expectancy of less than one year.
- An immunodeficiency syndrome
- An organ transplant is expected within 6 months of enrollment
- 3 or more previous new AV graft or fistula placements have occurred.
- Body habitus (e.g., extremely small or obese arms( precludes HVS device implantation or access.
Sites / Locations
- Robert Scribner
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Hemoaccess Valve System
Arm Description
Valve system for use with AV graft
Outcomes
Primary Outcome Measures
Unassisted patency rate
Determine if the ability to limit blood flow to an AV graft only when it is needed for dialysis will increase unassisted patency rate of the test arm by a minimum of 50%. The New England Journal of Medicine study, "Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency" (NEJM 360;21, 5/21/09) indicated a 1 year unassisted patency rate of 23% (77% required intervention). Our objective is to determine if the intervention rate can be reduced to 38-39% during the study, a 50% reduction in the expected intervention rate.
Secondary Outcome Measures
Eliminate Post-Dialysis Needle Site Bleeding
Outcome measure: Reduce post-dialysis needle site bleeding by 95%.
Currently most dialysis patients experience mild to severe post-dialysis bleeding when the large (15 gauge) dialysis needles are removed from their AV graft. The HVS device shuts off blood flow to the graft after dialysis therefore no post-dialysis bleeding should be experienced.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01644526
Brief Title
A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
Official Title
A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
Study Type
Interventional
2. Study Status
Record Verification Date
January 2018
Overall Recruitment Status
Terminated
Why Stopped
An enhanced device has been developed
Study Start Date
January 2016 (Actual)
Primary Completion Date
June 30, 2017 (Actual)
Study Completion Date
July 31, 2017 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Diaxamed LLC
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The ability to selectively control blood flow through an arteriovenous (AV) graft only when it is needed for dialysis may reduce the current repetitive complications such as thrombosis, venous hypertension post-dialysis bleeding, and blood steal from the extremities. The Hemoaccess Valve System (HVS) allows an AV graft to be turned on to blood flow when it is needed for dialysis then when dialysis is concluded, the device shuts off arterial blood flow and residual blood in the graft is flushed back into the body, using the dialysis blood lines. Once the graft is cleared of blood, the venous valve is then closed. Heparinized sterile saline reside in the graft between dialysis sessions. By having only saline in the graft and restoring normal blood flow to the artery and vein, it is believed that this will dramatically reduce the current complications associated with now having blood diverted through the graft 24/7.
Detailed Description
The Hemoaccess Valve System (HVS) is a subcutaneous valve device that is implanted when a new AV graft is placed. A saline pump delivers fluid to the arterial balloon valve and closes that end of the graft off to blood flow. Using the dialysis blood lines, saline flushes residual blood from the graft back into the body. Then the venous balloon valve closes and heparinized saline resides in the graft between dialysis sessions.
When the patient returns for dialysis, the dialysis technician deflates the valves and allows blood to flow to the graft for dialysis. (The saline inside the graft simply enters the blood stream.)
By only having saline inside the AV graft between dialysis sessions, there is no post-dialysis bleeding where the dialysis needles were cannulated, and because blood flow is restored to its normal course in the vein and artery, the traditional turbulent blood flow through the graft is eliminated, reducing the traditional complications caused when arterial blood is diverted through the graft then into the vein.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
End Stage Renal Disease
Keywords
dialysis, vascular access, arteriovenous grafts, valve system
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
6 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Hemoaccess Valve System
Arm Type
Experimental
Arm Description
Valve system for use with AV graft
Intervention Type
Device
Intervention Name(s)
Hemoaccess Valve System
Intervention Description
Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
Primary Outcome Measure Information:
Title
Unassisted patency rate
Description
Determine if the ability to limit blood flow to an AV graft only when it is needed for dialysis will increase unassisted patency rate of the test arm by a minimum of 50%. The New England Journal of Medicine study, "Effect of Dipyridamole plus Aspirin on Hemodialysis Graft Patency" (NEJM 360;21, 5/21/09) indicated a 1 year unassisted patency rate of 23% (77% required intervention). Our objective is to determine if the intervention rate can be reduced to 38-39% during the study, a 50% reduction in the expected intervention rate.
Time Frame
12 months
Secondary Outcome Measure Information:
Title
Eliminate Post-Dialysis Needle Site Bleeding
Description
Outcome measure: Reduce post-dialysis needle site bleeding by 95%.
Currently most dialysis patients experience mild to severe post-dialysis bleeding when the large (15 gauge) dialysis needles are removed from their AV graft. The HVS device shuts off blood flow to the graft after dialysis therefore no post-dialysis bleeding should be experienced.
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Be a candidate for a new arteriovenous graft
Be either currently on dialysis or ready to begin dialysis as soon as the access device (AV graft with Hemoaccess Valve System) is ready for use.
Be prepared to receive dialysis at dialysis centers in proximity of study centers
Have an outflow vein of greater than or equal to 3mm in diameter to which the graft can be successfully anastomosed.
Be able to communicate with study personnel.
Be considered by the physician to be readily available for subsequent visits.
Be willing to comply with all aspects of the treatment and evaluation as directed over the duration of the study.
Allow representatives of the Sponsor, the designated Clinical Research Organization, the Institutional Review Board and the FDA to review his/her relevant medical records that pertain to this study.
Exclusion Criteria:
An identification of a central venous stenosis on the ipsilateral side is documented or otherwise identified
An identification of an arterial venous stenosis on the ipsilateral side is documented or otherwise identified
A hypercoagulable state is documented or otherwise identified and/or previous AV access failures have occurred without an identifiable cause.
Has a life expectancy of less than one year.
An immunodeficiency syndrome
An organ transplant is expected within 6 months of enrollment
3 or more previous new AV graft or fistula placements have occurred.
Body habitus (e.g., extremely small or obese arms( precludes HVS device implantation or access.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Robert Scribner
Organizational Affiliation
CEO
Official's Role
Study Director
Facility Information:
Facility Name
Robert Scribner
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29615
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Pilot Study To Evaluate The CreatiVasc Hemoaccess Valve System In Patients Requiring Arteriovenous Graft Placement
We'll reach out to this number within 24 hrs